Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus

J Int Med Res. 1995 Nov-Dec;23(6):492-6. doi: 10.1177/030006059502300612.

Abstract

The effects of administration of an alpha-glucosidase inhibitor and a sulphonylurea compound on lipid profile were investigated in patients with non-insulin-dependent diabetes mellitus, (NIDDM) previously treated with sulphonylurea compounds alone, but in whom metabolic control was inadequate. A group of patients (n = 10) were treated with the alpha-glucosidase inhibitor at a dose of 0.2 mg, three times daily, for 4 weeks. Treatment significantly reduced the post-prandial glucose level and the serum total cholesterol level. In addition, there were non-significant reductions in the triglyceride and very low density lipoprotein levels. These preliminary results suggest that administration of alpha-glucosidase inhibitors might improve the lipid profile of patients with NIDDM.

Publication types

  • Clinical Trial

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, VLDL / blood
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Drug Therapy, Combination
  • Eating
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Glyburide / therapeutic use*
  • Glycoside Hydrolase Inhibitors*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Lipids / blood*
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Tolbutamide / therapeutic use*
  • Triglycerides / blood

Substances

  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, VLDL
  • Enzyme Inhibitors
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Lipids
  • Lipoproteins
  • Triglycerides
  • lipoprotein cholesterol
  • Cholesterol
  • Tolbutamide
  • Glyburide